Previous 10 | Next 10 |
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scie...
Gainers: ATA (NASDAQ: ATAI ) +97% . Provention Bio (NASDAQ: PRVB ) +29% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +24% . Chimerix (NASDAQ: CMRX ) +22% . FARO Technologies (NASDAQ: FARO ) +17% . Soliton (NASDAQ: SOLY ) +15% . GEE Group (NYSEMKT: JOB ) +14% . Geron (NASDAQ: GERN ) ...
Vaxart (NASDAQ: VXRT ) -37% on pricing stock offering. More news on: Vaxart, Inc., Zogenix, Inc., Zosano Pharma Corporation, Stocks on the move, Read more ...
Vaxart (NASDAQ: VXRT ) has priced its public offering of 9.1M common shares (including pre-funded warrants to purchase up to 8.2M common stock), and common warrants to purchase the same amount of shares at $1.10 per share and warrant, for gross proceeds of ~$10M. More news on: Vaxart, In...
Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public offering of 9,090,010 shares of common stock (which includes p...
Gainers: Nordic American Offshore (NYSE: NAO ) +33%. Melinta Therapeutics (NASDAQ: MLNT ) +23% . New Age Beverages (NASDAQ: NBEV ) +21% . Celldex Therapeutics (NASDAQ: CLDX ) +18% . Reliv International (NASDAQ: RELV ) +18% . Niu Technologies (NASDAQ: NIU ) +18% . Laredo Petrol...
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in April. Vaxart will present the following: Post...
Vaxart (NASDAQ: VXRT ) completes dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine. More news on: Vaxart, Inc., Healthcare stocks news, Stocks on the move, Read more ...
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the completion of dosing of the lead-in cohort in the Ph...
Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 p...
News, Short Squeeze, Breakout and More Instantly...
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursd...
— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and noroviru...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...